Alchemia banks on 2010

By Dylan Bushell-Embling
Thursday, 02 October, 2008

Alchemia [ASX: ACL] has recorded an $11 million loss for the financial year but reports a healthy cash reserve of $15.3 million.

Equity increased from around $87 million to $102 million.

The company expects to go into profit in 2010. Its generic fondaparinux, a copy of GSK’s Arixta, for venous thromboembolism, is scheduled for market launch in the US next year through its partner Dr Reddy’s.

Related News

Novel antibiotic activates 'suicide' mechanism in superbug

Researchers have discovered a new class of antibiotic that selectively targets Neisseria...

Modifications in the placenta linked to psychiatric disorders

Schizophrenia, bipolar disorder and major depression disorder are the neuropsychiatric disorders...

ADHD may be linked with an increased risk of dementia

An adult brain affected by attention deficit hyperactivity disorder (ADHD) presents modifications...


  • All content Copyright © 2025 Westwick-Farrow Pty Ltd